Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Antipsychotic drug use after aSAH signals more severe brain injury

14 Jun 2019

Use of antipsychotic drugs (APDs) in survivors of aneurysmal subarachnoid haemorrhage (aSAH) correlates with the extent of brain injury from aSAH, such that APD exposure is minimal in the absence of significant brain injury, a study has found.

Researchers looked at patterns of APD use in 1,144 consecutive aSAH patients alive at 12 months of index event and in 3,432 matched controls over a median follow-up of 9 years. Drug purchase and hospital discharge data were obtained using the Finish nationwide health registries.

First-time APD use was recorded in 140 patients (12 percent) after the index aSAH event and in 145 controls (4 percent). The cumulative rate of initiating APD was 6 percent at 1 year and 9 percent at 5 years in the aSAH group and 1 percent and 2 percent, respectively, in the control group.

In the subgroup of 489 patients with a good condition (modified Rankin Scale score of 0 or 1 at 12 months; no shunt, intracerebral haemorrhage or intraventricular haemorrhage) both at admission and at 12 months after aSAH, the cumulative rates of APD use at 1 and 5 years were only 1 percent and 2 percent.

The highest cumulative rate of APD use was 23 percent at 5 years, which was recorded among the 192 patients shunted for hydrocephalus after aSAH.

Of the aSAH patients with APD exposure, 88 (63 percent) also used antidepressant or antiepileptic drug concomitantly.

The present data suggest that APD use after aSAH may be used as a marker of more severe brain injury and forecast a worse long-term overall outcome, the researchers said. Furthermore, the possibility of psychotic disorders should be considered in outpatient clinics treating aSAH survivors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.